These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35723068)

  • 1. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
    Vysyaraju NR; Paul M; Ch S; Ghosh B; Biswas S
    J Drug Target; 2022 Dec; 30(10):1088-1105. PubMed ID: 35723068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
    Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
    Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
    Mazzucchelli S; Truffi M; Baccarini F; Beretta M; Sorrentino L; Bellini M; Rizzuto MA; Ottria R; Ravelli A; Ciuffreda P; Prosperi D; Corsi F
    Sci Rep; 2017 Aug; 7(1):7505. PubMed ID: 28790402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional Novel Nanoplatform for Effective Synergistic Chemo-Photodynamic Therapy of Breast Cancer by Enhancing DNA Damage and Disruptions of Its Reparation.
    Huang Z; Xian T; Meng X; Hu H; Gao L; Huang J; Yang D; Ou K; Wang B; Zhang Y
    Molecules; 2023 Oct; 28(19):. PubMed ID: 37836815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.
    Liu Z; Mao S; Dai L; Huang R; Hu W; Yu C; Yang Y; Cao G; Huang X
    Bioorg Med Chem; 2024 Nov; 113():117936. PubMed ID: 39369565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
    Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
    Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models.
    Cavanagh RJ; Monteiro PF; Moloney C; Travanut A; Mehradnia F; Taresco V; Rahman R; Martin SG; Grabowska AM; Ashford MB; Alexander C
    Biomater Sci; 2024 Mar; 12(7):1822-1840. PubMed ID: 38407276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
    Wang W; Xiong Y; Hu X; Lu F; Qin T; Zhang L; Guo E; Yang B; Fu Y; Hu D; Fan J; Qin X; Liu C; Xiao R; Chen G; Li Z; Sun C
    Acta Biomater; 2023 Feb; 157():428-441. PubMed ID: 36549633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human serum albumin-poly(Lactide)-conjugated self-assembly NPs for targeted docetaxel delivery and improved therapeutic efficacy in oral cancer.
    Kumbham S; Ghosh A; Ghosh B; Biswas S
    Int J Biol Macromol; 2022 Dec; 222(Pt A):1287-1303. PubMed ID: 36191788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131.
    Liu S; Liu H; Sun H; Deng S; Yue L; Weng Z; Yang J; Zuo B; He Y; Zhang B
    Anticancer Drugs; 2022 Jan; 33(1):19-29. PubMed ID: 34261920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.
    Scully MA; Wilkins DE; Dang MN; Hoover EC; Aboeleneen SB; Day ES
    Mol Pharm; 2023 Aug; 20(8):3895-3913. PubMed ID: 37459272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer.
    Hu H; Zhang Y; Ji W; Mei H; Wu T; He Z; Wang K; Shi C
    J Microencapsul; 2022 Jan; 39(1):25-36. PubMed ID: 34859741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer.
    Ghadi R; Pandey PK; Gabhale A; Wadikar A; Dharshini M; Kuche K; Date T; Jain S
    Int J Pharm; 2023 Dec; 648():123570. PubMed ID: 37918494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
    Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
    Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.